Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jin Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2942-8604; OpenAlex author ID A5032653173. Sources: OpenAlex.

Their work

Papers
136 (first author 17, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
152
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 4 papers · 2014: 7 papers · 2015: 10 papers · 2016: 12 papers · 2017: 12 papers · 2018: 15 papers · 2019: 13 papers · 2020: 11 papers · 2021: 14 papers · 2022: 4 papers · 2023: 9 papers · 2024: 8 papers · 2025: 7 papers · 2026: 5 papers

Papers 50 of 136

  1. Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.05.012↗
  2. Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.08.012↗
  3. GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence. Last author DOI 10.1016/j.tranon.2026.103044↗
  4. ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.09.032↗
  5. Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibi… Co-author DOI 10.1136/gutjnl-2025-336235↗
  6. Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing. Last author DOI 10.1007/s12672-025-02293-w↗
  7. The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway. Last author DOI 10.1016/j.tranon.2025.102346↗
  8. SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1. Last author DOI 10.1097/cm9.0000000000003640↗
  9. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  10. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  11. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Co-author DOI 10.1136/gutjnl-2024-332782↗
  12. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334361↗
  13. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. Co-author DOI 10.1007/s12033-023-00875-z↗
  14. Targeting CA9 restricts pancreatic cancer progression through pH regulation and ROS production. Co-author DOI 10.1007/s13402-024-01022-9↗
  15. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.csbj.2024.04.021↗
  16. Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ebiom.2024.105098↗
  17. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. First author DOI 10.1016/j.surg.2023.12.019↗
  18. Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. First author DOI 10.1038/s41416-024-02631-9↗
  19. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. First author DOI 10.1158/0008-5472.can-23-3596↗
  20. NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation. Co-author DOI 10.1186/s12885-024-11842-5↗
  21. Stress granules dynamics and promising functions in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2023.188885↗
  22. Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Last author DOI 10.1016/j.csbj.2023.04.003↗
  23. Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxi… Co-author DOI 10.1016/j.tranon.2023.101692↗
  24. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. First author DOI 10.1016/j.xcrm.2023.101234↗
  25. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Prelimin… Last author DOI 10.3390/curroncol30030228↗
  26. Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Can… Last author DOI 10.3390/ijms24043270↗
  27. Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer. Last author DOI 10.3390/ijms24043476↗
  28. Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges. Last author DOI 10.3390/ijms24043559↗
  29. [Progress and reflection of conversion therapy for locally advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20230329-00128↗
  30. Construction of a paclitaxel-related competitive endogenous RNA network and identification of a potential regulatory axis in pancreatic cancer. Last author DOI 10.1016/j.tranon.2022.101419↗
  31. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Co-author DOI 10.1038/s41388-022-02306-w↗
  32. Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/bib/bbab388↗
  33. The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1155/2022/4148805↗
  34. Emerging roles of the solute carrier family in pancreatic cancer. First author DOI 10.1002/ctm2.356↗
  35. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00018-021-03866-y↗
  36. Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). Co-author DOI 10.1016/j.hbpd.2020.12.020↗
  37. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  38. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. Co-author DOI 10.1186/s12943-021-01400-z↗
  39. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic rev… Co-author DOI 10.21037/gs-21-16↗
  40. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.648917↗
  41. Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. Co-author DOI 10.3389/fonc.2021.640820↗
  42. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.643465↗
  43. A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.650266↗
  44. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.674897↗
  45. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. First author DOI 10.3390/ijms222010944↗
  46. Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. Co-author DOI 10.7150/ijbs.59117↗
  47. Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. First author DOI 10.7150/thno.56174↗
  48. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.2895↗
  49. Hypoxia: a barricade to conquer the pancreatic cancer. First author DOI 10.1007/s00018-019-03444-3↗
  50. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. First author DOI 10.1080/15548627.2019.1628540↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 130 shared papers, 2011–2026 · strength 13.93
  2. Si Shi · 88 shared papers, 2012–2026 · strength 10.53
  3. Jie Hua · 50 shared papers, 2018–2026 · strength 6.73
  4. Qingcai Meng · 52 shared papers, 2017–2026 · strength 6.61
  5. Chen Liang · 57 shared papers, 2016–2025 · strength 6.24
  6. Wei Wang · 22 shared papers, 2021–2025 · strength 3.65
  7. Quanxing Ni · 49 shared papers, 2012–2020 · strength 3.13
  8. Bo Zhang · 20 shared papers, 2017–2024 · strength 2.66
  9. Yi Qin · 33 shared papers, 2013–2024 · strength 2.43
  10. Rong Tang · 15 shared papers, 2020–2026 · strength 2.40
  11. Chen Liu · 40 shared papers, 2011–2025 · strength 2.12
  12. Shunrong Ji · 28 shared papers, 2013–2025 · strength 1.83
  13. Jiang Long · 37 shared papers, 2011–2018 · strength 1.72
  14. Zhen Tan · 11 shared papers, 2020–2025 · strength 1.66
  15. Liang Liu · 33 shared papers, 2013–2019 · strength 1.64
  16. Miaoyan Wei · 10 shared papers, 2019–2026 · strength 1.49
  17. Wenyan Xu · 23 shared papers, 2014–2025 · strength 1.45
  18. Dingkong Liang · 21 shared papers, 2015–2019 · strength 1.35
  19. Guopei Luo · 23 shared papers, 2011–2025 · strength 1.33
  20. Zeyin Rong · 7 shared papers, 2021–2026 · strength 1.23
  21. Mingming Xiao · 5 shared papers, 2024–2026 · strength 1.17
  22. Kaizhou Jin · 17 shared papers, 2015–2025 · strength 1.16
  23. Jiang Liu · 11 shared papers, 2015–2021 · strength 1.07
  24. Yiyin Zhang · 10 shared papers, 2018–2023 · strength 1.05
  25. Jianhui Yang · 4 shared papers, 2021–2026 · strength 0.88

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.